SUNNYVALE, Calif., April 26, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the launch of the Prostate Advances in Comparative Evidence (PACE) Study, an international, multi-center, randomized study to compare CyberKnife® Stereotactic Body Radiation Therapy (SBRT), da Vinci assisted and manual laparoscopic surgery and conventionally fractionated intensity modulated radiation therapy (IMRT), for the treatment of localized prostate cancer. The PACE Study aims to build upon the strong foundation of published evidence for CyberKnife prostate SBRT by creating comparative evidence to support its future potential as the gold standard in the treatment of organ confined prostate cancer. This information will enable clinicians and patients to make informed treatment decisions based on the highest level of clinical evidence.
Currently, there is no clear gold standard for localized prostate cancer treatment. A lack of comparative clinical data has prevented definitive conclusions to be drawn as to which therapy can be considered the preferred treatment for localized prostate cancer. Treatment decisions have often been made based on historical experience, aged comparisons of older treatment techniques or single modality experiences. Physicians and leading industry groups, including The Agency for Healthcare Quality and Research (AHRQ) and the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC), have called for a randomized study comparing the most popular treatment options to bring clarity to the treatment landscape.
The PACE Study was created by a consortium of leading academic centers in Europe—including Royal Marsden NHS Foundation Trust in the UK, Center Oscar Lambret in France, Charite–Universitatsmedizin in Germany, Erasmus MC-Daniel den Hoed Cancer Center in The Netherlands, and Mount Vernon Cancer Centre in the UK and is comprised of two parallel randomized arms:
- Patients considered candidates for surgery, either by clinician recommendation or patient choice, are randomized to either laparoscopic prostatectomy (performed manually or through robotic assistance using da Vinci) or CyberKnife prostate SBRT.
- Non-surgical candidates or patients who refuse surgery will be randomized to either CyberKnife prostate SBRT or conventionally fractionated IMRT.
The ultimate goal of the study is to compare the outcomes of CyberKnife prostate SBRT, in terms of efficacy, toxicity and quality of life to da Vinci prostatectomy, manual laparoscopic prostatectomy and conventionally fractionated IMRT for early-stage, organ-confined prostate cancer. The study employs the leading quality of life tools to measure erectile function preservation, urinary and rectal toxicity, urinary incontinence and other scores related to general post treatment side effects. The study is expected to involve 30-40 centers globally and accrue more than 1,000 patients who will be followed for 10 years. The study leaders anticipate collecting and reporting data outcomes at several interim points including one, two and five years post-treatment.
"In light of a lack of definitive, comparative data supporting any one option as the best treatment choice, about 75 percent of low risk prostate cancer patients in the US receive surgery," said Dr. Nicholas van As, M.D, consultant clinical oncologist at the Royal Marsden NHS Foundation Trust in London. "The goal of the PACE study is to create the data needed to compare outcomes of treatment with CyberKnife prostate SBRT to surgery and IMRT, which are the accepted standard treatments for organ confined prostate cancer, to allow informed treatment decisions to be made."
"An increasing number of patients are attracted to treatment with the CyberKnife System due to its unique ability to precisely treat the prostate while avoiding surrounding healthy tissue and critical structures, offering an effective treatment for early-stage prostate cancer," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "The rapidly expanding base of CyberKnife prostate SBRT published studies supports the benefits of this treatment for patients. Accuray believes in taking the lead in supporting studies, such as the PACE study, that will generate clinical data to support the benefits of technical innovation and provide the highest level of comparative evidence for the benefit of prostate cancer patients worldwide."
Since 2002 CyberKnife prostate SBRT also known as radiosurgery emerged as a viable treatment option for prostate cancer it has quickly gained acceptance due to the combination of favorable clinical outcomes, as well as unique quality of life benefits for patients during and post-treatment. To date, 14 peer-reviewed studies involving more than 700 patients have been published showing the long term efficacy of the non-invasive CyberKnife System, the most widely-used radiosurgery and SBRT device, in terms of disease-free survival, toxicity, and preservation of sexual function. Based on the data, including five-year patient outcomes, most Medicare carriers across the country now provide coverage for prostate cancer patients seeking treatment with the CyberKnife System.
Complete information about the PACE Study is available at http://www.clinicaltrials.gov/ct2/show/NCT01584258. More information about CyberKnife prostate SBRT is available at www.cyberknifeforprostate.com.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, more than 300,000 patients worldwide have been treated using the Company's technologies and more than 616 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical effectiveness & outcomes, standards of treatment, reimbursement, and clinical study results. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the Company's report on Form 10-K for fiscal year 2011, and its reports on Form 10-Q for the first and second quarters of fiscal 2012.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Euan Thomson, Ph.D.
SOURCE Accuray Incorporated